Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3630678 | 0.90 | MAPK14 (0.52) | MAPK14RAB9AKMT2AMEN1RAF1 | |
| SCHEMBL6049563 | 0.88 | MAPK14 (0.44) | MAPK14KMT2AMEN1RAF1KDR | |
| SCHEMBL6049562 | 0.86 | MAPK14 (0.56) | MAPK14MDM2RAB9AKMT2AMEN1 | |
| SCHEMBL3623372 | 0.85 | BRAF (0.47) | MAPK14RAF1KDRFLT3 | |
| SCHEMBL1287890 | 0.84 | CCNC (0.55) | MAPK14RAB9AKMT2AMEN1RAF1 | |
| SCHEMBL3629146 | 0.84 | RAF1 (0.56) | MAPK14RAF1KDR | |
| SCHEMBL6049646 | 0.81 | NAMPT (0.46) | MAPK14KMT2AMEN1KDRSMN1; SMN2 | |
| SCHEMBL7836573 | 0.79 | MAPK14 (0.48) | MAPK14PTK2KMT2ARAF1AURKB | |
| SCHEMBL6050040 | 0.76 | MAPK14 (0.52) | MAPK14RAB9AKMT2AMEN1TAAR1 | |
| SCHEMBL668689 | 0.76 | MAPK14 (0.62) | MAPK14MDM2PTK2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4403482-B2 | — | — | 2010-01-27 | — | — | JP | claimed |
| EP-1041982-A4 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER PHARMACEUTICALS CORP (US) | 2006-06-14 | — | — | EP | claimed |
| JP-2001526223-A | — | — | 2001-12-18 | — | — | JP | claimed |
| EP-1047418-A4 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER AG (US) | 2001-02-07 | — | — | EP | claimed |
| EP-1047418-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | Bayer Corporation (US) | 2000-11-02 | — | — | EP | claimed |
| EP-1041982-A1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | Bayer Corporation (US) | 2000-10-11 | — | — | EP | claimed |
| WO-1999032106-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | claimed |
| WO-1999032111-A1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | claimed |
| EP-1041982-A4 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER PHARMACEUTICALS CORP (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1047418-A4 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER AG (US) | 2001-02-07 | — | — | EP | disclosed |
| EP-1047418-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | Bayer Corporation (US) | 2000-11-02 | — | — | EP | disclosed |
| EP-1041982-A1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | Bayer Corporation (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032106-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032111-A1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |